Evidence map›Paper›PMID 34190429›Full record

ArticleCancer medicine2021

Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer.

Sandi L Pruitt, David E Gerber, Hong Zhu, Daniel F Heitjan, Bhumika Maddineni, Danyi Xiong, Amit G Singal, Anna Tavakkoli, Ethan A Halm, Caitlin C Murphy

Abstract read
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sandi L PruittDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-1007-9176
David E GerberDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-7812-6741
Hong ZhuDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-8562-3351
Daniel F HeitjanDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Bhumika MaddineniDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Danyi XiongDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Amit G SingalDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Anna TavakkoliDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-9921-9085
Ethan A HalmDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Caitlin C MurphyDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-9365-0691

Funding

Revisiting Prior Cancer as an Exclusion Criterion for Cancer Clinical TrialsR01CA229834 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI PRUITT, SANDI LEIGH · 2018 to 2023
$2.9M
Development of New Cancer Treatments and InvestigatorsK24CA201543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GERBER, DAVID ERIC · 2016 to 2020
$737k
NCI NIH HHS K24 CA201543NCI NIH HHS R01 CA229834
6 · The paper itself

Abstract

Patients with previous cancer are often excluded from clinical trials despite limited evidence about their prognosis. We examined the effect of previous cancer on overall and colorectal cancer (CRC)-specific survival of patients newly diagnosed with CRC. This population-based cohort study from the U.S.A. included patients aged ≥66 years and diagnosed with CRC between 2005 and 2015 in linked Surveillance, Epidemiology, and End Results-Medicare data. We estimated the stage-specific effects of a previous cancer on overall survival using Cox regression and on CRC-specific survival using competing risk regression. We also examined the effect of previous cancer type, timing, and stage on overall survival. Of 112,769 patients, 14.1% were previously diagnosed with another cancer--commonly prostate (32.9%) or breast (19.4%) cancer, with many (47.1%) diagnosed <5 years of CRC. For all CRC stages except IV, in which there was no difference, patients with previous cancer (vs. without) had worse overall survival. However, patients with previous cancer had improved CRC-specific survival. Overall survival for those with stage 0-III CRC varied by previous cancer type, timing, and stage; for example, patients with previous melanoma had overall survival equivalent to those with no previous cancer. Our results indicate that, in general, CRC patients with previous cancer have worse overall survival but superior CRC-specific survival. Given their equivalent survival to those without previous cancer, patients with previous melanoma and those with stage IV CRC with any type of previous cancer should be eligible to participate in clinical trials.

Indexed as

Cancer SurvivorsAgedAged, 80 and overBreast NeoplasmsCause of DeathCohort StudiesColorectal NeoplasmsFemaleHumansLung NeoplasmsMaleMelanomaNeoplasms, Second PrimaryNeoplasm StagingProportional Hazards ModelsProstatic Neoplasmsclinical trialscolorectal cancerrectal cancersurvival

Identifiers

PMID34190429
PMCPMC8290226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.